Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1;30(9):609-613.
doi: 10.1097/PAI.0000000000001048. Epub 2022 Jul 26.

Comprehensive Molecular Profiling of Oncocytic Salivary Gland Malignancies

Daniel J Zaccarini  1 , Abirami Sivapiragasam  1 , Ethan Sokol  2 , Richard S P Huang  2 , Dean C Pavlick  2 , Tyler Janovitz  2 , Michele R Nasr  1 , Jeffrey S Ross  1   2
Affiliations

Comprehensive Molecular Profiling of Oncocytic Salivary Gland Malignancies

Daniel J Zaccarini et al. Appl Immunohistochem Mol Morphol. .

Abstract

Oncocytic histologic features can be seen in a variety of salivary gland carcinomas. We performed a comprehensive molecular profiling of 15 salivary gland malignancies with oncocytic features (diagnosed as oncocytic carcinoma, carcinoma NOS with oncocytic features, or salivary duct carcinoma with oncocytic features). We reveal multiple novel molecular alterations that have not been previously described in other salivary gland malignancies, including, but not limited to, KEL amplification (13.3%, 2/15), PARP1 amplification (13.3%, 2/15), and EPHB4 amplification (13.3%, 2/15). Alterations in KMT2C (13.3%, 2/15), ERBB3 (13.3%, 2/15), CTNNA1 (13.3%, 2/15), and SMAD4 (20%, 3/15) were also found in this series and have been reported in other salivary gland malignancies. Alterations that have been reported in salivary duct carcinoma were also identified, including TP53 (40%, 6/15) , ERBB2 mutations (13.3%, 2/15) , ERBB2 amplification (13.3%, 2/15), PIK3CA (26.7%, 4/15) , PTEN (20%, 3/15), BRCA2 (20%, 3/15), BRAF (20%, 3/15), CDKN2A/B (20%, 3/15), CDH1 (13.3%, 2/15), and HRAS (13.3%, 2/15). Oncocytic salivary gland malignancies are a molecularly heterogenous group of tumors with partial overlap with salivary duct carcinoma subtypes.

PubMed Disclaimer

Conflict of interest statement

E.S., R.S.P.H., D.C.P., T.J., J.S.R. are employees of Foundation Medicine, Inc., which is a wholly owned subsidiary of Roche and hold equity in Roche Holdings. The remaining authors declare no conflict of interest.

References

    1. Bishop JA, Nakaguro M, Whaley RD, et al. Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33–RET fusions and BRAF V600E mutations. Histopathology. 2021;79:338–346.
    1. Chiosea SI, Thompson LD, Weinreb I, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016;122:3136–3144.
    1. Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. World J Surg Oncol. 2016;22:4623–4633.
    1. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Genome Nucleic Acids Res 2015;43(D1):D805–811.
    1. Lei L, Van Staalduinen E, Troxell M, et al. Mammary lobular carcinoma-like salivary gland carcinoma: report of a rare case. Head Neck Pathol. 2021;43:1–8.

MeSH terms

Substances